Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells
- PMID: 2481664
- PMCID: PMC5917909
- DOI: 10.1111/j.1349-7006.1989.tb02265.x
Augmentation of murine lymphokine-activated killer cell induction by a factor produced by Nocardia rubra cell wall skeleton-stimulated T cells
Abstract
Four-hour exposure of C3H/HeN mouse spleen cells to Nocardia rubra cell wall skeleton (N-CWS) before 4-day culture with a suboptimal dose of human recombinant interleukin 2 (rIL 2) augmented the induction of lymphokine-activated killer (LAK) cell activity, whereas the treatment with N-CWS alone induced no cytotoxicity. In accordance with this, the IL 2 binding activity of spleen cells was augmented by combined stimulation with N-CWS and rIL 2. The augmented cytotoxicity was mediated by Thy-1.2+, Lyt-1.1-, Lyt-2.1- and asialo GM1+ cells. Cell cultures in diffusion chambers revealed that N-CWS-treated spleen cells produced a LAK cell induction-helper factor (LAK-helper factor, LHF) when cultured with rIL 2. The LHF production required Thy-1.2+, Lyt-1.1+, Lyt-2.1+ and asialo GM1- cells, and the coexistence of unstimulated accessory cells was also essential for the LHF production. Cells responding to both LHF and rIL 2 to generate LAK activity were Thy-1.2-, Lyt-1.1-, Lyt-2.1- and asialo GM1+. The culture fluid of spleen cells stimulated with both N-CWS and rIL 2 contained no tumor necrosis factor (TNF) activity, and the additional stimulation with N-CWS caused no production of either IL 2 or interferon (IFN). Murine recombinant interleukin 1 alpha (Mu-rIL 1 alpha) could not replace the augmentative effect of N-CWS on LAK cell induction. These results suggest that in the presence of rIL 2, N-CWS stimulates murine T cells to produce LHF that is probably distinct from IL 1, IL 2, TNF and IFN.
Similar articles
-
Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.Jpn J Cancer Res. 1989 Nov;80(11):1089-97. doi: 10.1111/j.1349-7006.1989.tb02264.x. Jpn J Cancer Res. 1989. PMID: 2514171 Free PMC article.
-
Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).Cancer Immunol Immunother. 1989;30(4):195-204. doi: 10.1007/BF01665005. Cancer Immunol Immunother. 1989. PMID: 2598189 Free PMC article.
-
Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.Cancer Res. 1991 Oct 1;51(19):5261-5. Cancer Res. 1991. PMID: 1833049
-
Role of soluble cytotoxic factors in lymphokine-activated killer cell (LAK)-mediated cytotoxicity.Ann N Y Acad Sci. 1988;532:395-404. doi: 10.1111/j.1749-6632.1988.tb36357.x. Ann N Y Acad Sci. 1988. PMID: 3052213 Review. No abstract available.
-
Interleukin-2: its rationale and role in the treatment of patients with cancer.Cancer Treat Res. 1995;80:83-105. doi: 10.1007/978-1-4613-1241-3_4. Cancer Treat Res. 1995. PMID: 8821575 Review. No abstract available.
Cited by
-
Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.J Cancer Res Clin Oncol. 1991;117(2):109-14. doi: 10.1007/BF01613133. J Cancer Res Clin Oncol. 1991. PMID: 2007609 Free PMC article.
References
-
- ) Iigo , M. , Sakurai , M. , Tamura , T. , Saijo , N. and Hoshi , A.In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors . Cancer Res. , 48 , 260 – 264 ( 1988. ). - PubMed
-
- ) Rosenberg , S. A. , Schwarz , S. L. and Spiess , P. J.Combination immunotherapy for cancer: synergistic antitumor interactions of interleukin‐2, alfa interferon, and tumor‐infiltrating lymphocytes . J. Nat I. Cancer Inst. , 80 , 1393 – 1397 ( 1988. ). - PubMed
-
- ) McIntosh , J. K. , Múle , J. J. , Merino , M. J. and Rosenberg , S. A.Synergistic antitumor effects of immunotherapy with recombinant interleukin‐2 and recombinant tumor necrosis factor‐α . Cancer Res. , 48 , 4011 – 4017 ( 1988. ). - PubMed
-
- ) Owen‐Schaub , L. B. , Guttermann , J. U. and Grimm , E. A.Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: Effect of tumor necrosis factor α and interleukin 2 in the generation of human lymphokine‐activated killer cell activity . Cancer Res. , 48 , 788 – 792 ( 1988. ). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous